Hexagon Capital Partners LLC cut its holdings in Humana Inc. (NYSE:HUM – Get Rating) by 9.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 220 shares of the insurance provider’s stock after selling 23 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Humana were worth $113,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of HUM. Cibc World Market Inc. boosted its holdings in shares of Humana by 4.0% in the first quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock valued at $2,484,000 after acquiring an additional 217 shares in the last quarter. Blair William & Co. IL boosted its holdings in shares of Humana by 0.6% in the first quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock valued at $2,463,000 after acquiring an additional 32 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Humana by 0.5% in the first quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock valued at $2,135,000 after acquiring an additional 26 shares in the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Humana by 19.0% in the first quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock valued at $268,000 after acquiring an additional 98 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Humana by 25.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock valued at $12,971,000 after acquiring an additional 5,964 shares in the last quarter. 93.38% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Humana
In other Humana news, insider Joseph C. Ventura sold 2,048 shares of the firm’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $507.97, for a total transaction of $1,040,322.56. Following the transaction, the insider now owns 4,256 shares of the company’s stock, valued at approximately $2,161,920.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Joseph C. Ventura sold 2,048 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $507.97, for a total value of $1,040,322.56. Following the sale, the insider now directly owns 4,256 shares in the company, valued at approximately $2,161,920.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce D. Broussard sold 17,575 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $505.85, for a total transaction of $8,890,313.75. Following the completion of the sale, the chief executive officer now owns 70,040 shares in the company, valued at $35,429,734. The disclosure for this sale can be found here. 0.32% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Humana Trading Down 1.4 %
NYSE HUM opened at $491.35 on Friday. Humana Inc. has a 12 month low of $410.87 and a 12 month high of $571.30. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.52 and a quick ratio of 1.52. The company has a market capitalization of $61.41 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 1.24 and a beta of 0.72. The company’s fifty day moving average price is $495.47 and its two-hundred day moving average price is $507.71.
Humana (NYSE:HUM – Get Rating) last issued its earnings results on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.16. Humana had a net margin of 3.02% and a return on equity of 20.50%. The company had revenue of $22.44 billion for the quarter, compared to analysts’ expectations of $22.45 billion. During the same period in the prior year, the company earned $1.24 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year. As a group, research analysts predict that Humana Inc. will post 28.05 earnings per share for the current fiscal year.
Humana Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be paid a dividend of $0.885 per share. This is a boost from Humana’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Thursday, March 30th. This represents a $3.54 annualized dividend and a yield of 0.72%. Humana’s dividend payout ratio (DPR) is presently 16.06%.
Humana Profile
Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.
Featured Articles
- Get a free copy of the StockNews.com research report on Humana (HUM)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Carvana May Be Able To Reach Profitability This Year
- Low Volume Bunge Plunge Presents an Opportunity
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Get Rating).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
